Medford, Oregon, 1 August 2019 - The Institute for Arctic and Antarctic Biodiscovery (IAAB), the world’s first R&D organizationdedicated to drug discovery from the polar regions, announced today that it has successfully completed its inaugural diving expedition in the Norwegian Arctic. The IAAB 's first diving expedition was dedicated to bioprospecting – the targeted harvesting and documentation of diverse marine invertebrates and microorganisms – and was carried out in the Lofoten Islands in the Norwegian Sea. Biological specimens collected during these dives will next be used to isolate hundreds of drug-like biomolecules that will be screened for pharmaceutically useful bioactivities.
